GLENMARKNSEGlenmark Pharmaceuticals Limited· PharmaceuticalsLowNeutral
Announced Fri, 29 Aug · 18:50 IST

Glenmark Pharmaceuticals Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 26, 2025

Board & Shareholder Meetings View source PDF

GLENMARK · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Glenmark Pharmaceuticals has notified the stock exchanges that its 47th Annual General Meeting will be held on Friday, September 26, 2025 at 2:00 p.m. IST via video conferencing. Shareholders will vote on adopting the audited standalone and consolidated financial statements for FY25, declaring a dividend of ₹2.50 per equity share, re-appointing Mrs. Cherylann Pinto as Director, and appointing Walker Chandiok & Co. LLP as Statutory Auditors for a five-year term (with proposed FY26 remuneration of ₹16 million). Other items include ratifying the Cost Auditor's fee of ₹2.80 million, appointing Rauthan & Associates as Secretarial Auditor for five years (FY26–FY30), and confirming the appointment of Ms. Patricia Andrews as Non-Executive Independent Director for a five-year term. The record date for dividend eligibility is September 15, 2025, and the e-voting window runs from September 23 to September 25, 2025.

Likely market impact

Routine AGM notice with no negative news; confirms a ₹2.50 per share dividend for FY25 (subject to shareholder approval), which is supportive for income-focused investors. The auditor and director appointments are standard governance items and unlikely to move the stock on their own.